BioPharma Dive – AI / Data

Immutrin raises $87M to advance drug for progressive heart disease

Published

2 weeks ago

on

The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version